Fosun pharma (600196) announced on the evening of December 3 that the listing application for the Hans-like (also known as Sunitinib injection) developed by Henlius, in combination with pemetrexed and carboplatin, for the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with negative epidermal growth factor receptor (EGFR) gene mutations and negative anaplastic lymphoma kinase (ALK) has recently been approved by the National Medical Products Administration. In addition, the registration application for the peach blossom four-thing granules of the holding subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd. has recently been accepted by the National Medical Products Administration.
复星医药：控股子公司桃红四物颗粒药品注册申请获受理
Fosun pharma: The registration application for the peach blossom four-thing granules pharmaceutical of the holding subsidiary has been accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.